FindTrial
Sign In

A case records based retrospective study for Patients With Multiple Liver Metastases of Melanoma Treated by Cryoablation combined with Transarterial Infusion of Pembrolizumab (CATAP)

A case records based retrospective study for Patients With Multiple Liver Metastases of Melanoma Treated by Cryoablation combined with Transarterial Infusion of Pembrolizumab (CATAP)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024899
Enrollment
Unknown
Registered
2019-08-02
Start date
2019-07-24
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanoma

Interventions

Case series:Nil

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
32 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. histological diagnosis of melanoma; 2. with unresectable multiple/disseminated liver metastasis; 3. failure of first-line systemic therapies or liver-directed therapies, or refuse these treatments; 4. performance score 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

Exclusion criteria

Exclusion criteria: 1. receiving additional therapies except for these two treatment approaches before disease progression; 2. with other malignancies; 3. With active or a documented history of autoimmune disease.

Design outcomes

Primary

MeasureTime frame
Objective Response Rate;Progression-free Survival Time (PFS);—

Secondary

MeasureTime frame
Overall survival Time (OS);Adverse Events;—

Countries

China

Contacts

Public ContactWeijun Fan

Sun Yat-sen University Cancer Center

fanwj@sysucc.org.cn+86-13826154530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026